There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ultragenyx (NASDAQ: RARE), Regulus (NASDAQ: RGLS) and Mylan Inc (NASDAQ: MYL) with bullish sentiments.
Ultragenyx (NASDAQ: RARE)
In a report released today, Eric Schmidt from Cowen & Co. assigned a Buy rating to Ultragenyx (NASDAQ: RARE). The company’s shares opened today at $64.73.
According to TipRanks.com, Schmidt is a top 25 analyst with an average return of 44.1% and a 63.0% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Merrimack Pharmaceuticals, Adaptimmune Therapeutics, and Alexion Pharmaceuticals.
Currently, the analyst consensus on Ultragenyx is Strong Buy and the average price target is $71.64, representing a 10.7% upside.
In a report issued on May 9, Canaccord Genuity also reiterated a Buy rating on the stock with a $80 price target.
See today’s analyst top recommended stocks >>
Regulus (NASDAQ: RGLS)
Wedbush analyst Liana Moussatos reiterated a Buy rating on Regulus (NASDAQ: RGLS) today and set a price target of $3. The company’s shares opened today at $0.72, close to its 52-week low of $0.63.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 10.2% and a 45.7% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Global Blood Therapeutics, and Catabasis Pharmaceuticals.
Regulus has an analyst consensus of Moderate Buy, with a price target consensus of $1.79.
Mylan Inc (NASDAQ: MYL)
In a report released today, Rohit Vanjani from Guggenheim assigned a Buy rating to Mylan Inc (NASDAQ: MYL), with a price target of $59. The company’s shares opened today at $39.20.
According to TipRanks.com, Vanjani is a 4-star analyst with an average return of 10.8% and a 50.4% success rate. Vanjani covers the Healthcare sector, focusing on stocks such as Sienna Biopharmaceuticals Inc, Revance Therapeutics, and Endo International.
Currently, the analyst consensus on Mylan Inc is Moderate Buy and the average price target is $50.56, representing a 29.0% upside.
In a report issued on May 10, Mizuho Securities also reiterated a Buy rating on the stock with a $51 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
